From November 15th to 17th, 2023, the 3rd Annual Meeting of Chinese Society for Cell Therapy (CSCT), hosted by the Research and Application Branch of Cell Therapy, Chinese Society for Cell Biology, and the National Center of Technology Innovation for Biopharmaceuticals, and organized by BioBAY, was held grandly at the Suzhou International Expo Center. This conference was rich in content and full of highlights, attracting over 1,200 participants and more than 100 experts from research institutes, medical institutions, and enterprises to gather together to share their insights and spark intellectual exchanges.
SHEN Jianzhong, Deputy Director of the China National Center for Biotechnology Development (CNCBD), delivered a speech in which he reviewed that during the "13th Five-Year Plan" and "14th Five-Year Plan" periods, CNCBD, entrusted by relevant departments, undertook a number of major national science and technology projects in the field of biomedicine. He also expressed that the center will adhere to the goal of becoming a professional management institution for high-level national science and technology projects and a professional think tank in the field of biomedicine, strengthen strategic research in the field of biomedicine, innovate management mechanisms, and solidly implement major national science and technology projects in the field of biomedicine.
Researcher HUI Lijian, President of the Research and Application Branch of Cell Therapy, Chinese Society for Cell Biology, introduced the current research status of cellular and gene therapy in China, emphasizing the need to quickly and effectively establish bridges and ties between research institutions, medical facilities, and enterprises to facilitate the transfer and translation of research findings into clinical applications. Together, we should advance the development and industrialization of cellular therapies, ultimately maximizing the protection of patients' health and safety.
The White Paper on "Cell Therapy in China" was released at the opening ceremony of the conference. The White Paper was led by the Research and Application Branch of Cell Therapy, Chinese Society for Cell Biology, and co-organized by the Shanghai Center of Biomedicine Development. The Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and the Strategic Information Department of Shanghai Life Science Information Center were responsible for drafting it. From the perspectives of the development status, existing problems, and policy measures in the field of cell therapy in China, the White Paper elaborates on the opportunities and challenges faced by the country in this area. It serves as a reference for researchers, decision-making bodies, and regulatory agencies.
The meeting featured a total of eight themed sub-sessions, with Professor ZHAO Bing, Principal Scientist at bioGenous, chairing the sub-session on "Organoid Research and Applications". Professor LIN Xinhua, Dean of the School of Life Sciences at Fudan University and Director of the State Key Laboratory of Genetic Engineering, delivered an invited lecture titled "Application of Organoid Technology in the Pathogenesis of Viruses". The event concluded with a roundtable discussion focusing on "The Prospects of Organoid Technology in the Development of Cell Therapy Industry and Regenerative Medicine". The scene was vibrant with active exchanges, and the academic atmosphere was rich. The meeting presentations and roundtable forums were both fascinating and thought-provoking, sparking heated discussions and positive feedback.
The meeting invited top experts from both domestic and international cell therapy fields to engage in discussions and exchanges through keynote speeches, special lectures, poster presentations, and other forms. Focusing on the basic research, clinical application, and industrial promotion of cell and gene therapy, the event aimed to gain a deep understanding of the current status of cell therapy research and application in China, explore frontier scientific issues and key bottlenecks in the field, and promote cooperation and exchange between basic research, preclinical and clinical studies, and industrial transformation related to cell therapy. The conference aimed to drive the development of research and translational application in the field of cell therapy in China.
bioGenous was invited to participate in this annual conference on cell therapy in China and set up a business booth, which attracted close attention from participating experts. Professor HUI Lijian, President of the Research and Application Branch of Cell Therapy, Chinese Society for Cell Biology, and Professor HE Zhiying, Secretary-General of the same branch, fully affirmed the development achievements made by bioGenous. They highly recognized and expected bioGenous' complete solution from science to standardization for organoids and its CRO services for new drug development based on organoids. They had more expectations for bioGenous' future development, hoping that it could make increasing contributions to the development of the field of cell therapy in China.
bioGenous booth was overwhelmingly popular, attracting expert visit and guidance
bioGenous was invited to participate in this meeting and set up a business booth, which attracted close attention from participating experts. Professor HUI Lijian, President of the Research and Application Branch of Cell Therapy, Chinese Society for Cell Biology, and Professor HE Zhiying, Secretary-General of the same branch, fully affirmed the development achievements made by bioGenous. They highly recognized and expected bioGenous' complete solution from science to standardization for organoids and its CRO services for new drug development based on organoids. They had more expectations for bioGenous's future development, hoping that it could make increasing contributions to the development of the field of cell therapy in China.
The comprehensive standardized organoid solutions were all displayed, attracting numerous inquiries and exchanges from participating guests.
At this annual conference on cell therapy in China, bioGenous displayed its comprehensive and standardized organoid solutions, encompassing three key aspects: Standardization 1 - Growth factors optimized specifically for organoid culture, Standardization 2 - Whole-process reagent kits for multiple lineages and cancer types, and Standardization 3 - Organoid technology system services (CDMO). The bioGenous booth was bustling with continuous inquiries and exchanges from participating guests regarding these standardized organoid solutions.
Organoid-based CRO service for new drug research and development has attracted extensive attention from new drug research and development enterprises
During the meeting, bioGenous' CRO services for new drug development based on organoids, which cover all stages from drug screening and discovery, preclinical research, to clinical and post-marketing studies, garnered widespread attention and discussion among new drug R&D professionals in the field of cell therapy.
The bioGenous booth was incredibly popular during the meeting. Our representatives warmly welcomed every visitor, exchanged technical expertise, discussed industry developments, and shared with numerous attendees bioGenous' comprehensive standardized organoid solutions and CRO services for new drug development based on organoids. This allowed the attendees to deeply appreciate bioGenous' professionalism and potential value in the field of organoids!
